Yvonne Greenstreet - Mar 1, 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Chief Executive Officer, Director
Signature
By: Stephen Hall, Attorney-in-Fact For: Yvonne Greenstreet
Stock symbol
ALNY
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 04:20 PM
Previous filing
Feb 29, 2024
Next filing
Jun 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Award $0 +23.8K +49.36% $0.00 71.9K Mar 1, 2024 Direct F1, F2
holding ALNY Common Stock 407 Mar 1, 2024 by Managed Account F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Award $0 +46.4K $0.00 46.4K Mar 1, 2024 Common Stock 46.4K $152.61 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
F2 The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 23,754 newly awarded RSUs and 48,128 shares of common stock. The Reporting Person also holds 11,842 unvested RSUs that were previously reported in Table II.
F3 Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F4 The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vesting in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.